Literature DB >> 7623521

Effect of dotarizine on electroconvulsive shock or pentylenetetrazol-induced amnesia and on seizure reactivity in rats.

M Lazarova1, B Petkova, V D Petkov.   

Abstract

Dotarizine (DOT), a compound performing both as calcium antagonist and as 5-HT2 receptor antagonist, was evaluated for its ability to protect against electroconvulsive shock (ECS)- and pentylenetetrazol (PTZ)-induced performance deficit in a passive avoidance "step-down" task in rats. Its effect on electric and PTZ seizure models was also studied. DOT administered orally at a dose of 50 mg/kg for 5 days before learning had no significant effect on retention tests given 3 h, 24 h and 7 days after the training session. It should be noted, however, that DOT completely prevented ECS- and PTZ-induced amnesia in passive avoidance situation. DOT had a pronounced protective effect against electric seizures but did not affect PTZ seizures. The present results provide additional evidence for the role of serotonergic neurotransmitter system and calcium homeostasis for memory and seizure reactivity and may be important in the development of effective treatment strategies for memory dysfunction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7623521

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  3 in total

Review 1.  The role of different serotonin receptor subtypes in seizure susceptibility.

Authors:  Mohammad Hadi Gharedaghi; Mohammad Seyedabadi; Jean-Eric Ghia; Ahmad Reza Dehpour; Reza Rahimian
Journal:  Exp Brain Res       Date:  2013-11-14       Impact factor: 1.972

Review 2.  Central serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link?

Authors:  Bruno P Guiard; Giuseppe Di Giovanni
Journal:  Front Pharmacol       Date:  2015-03-17       Impact factor: 5.810

3.  Pentylenetetrazol and Morphine Interaction in a State-dependent Memory Model: Role of CREB Signaling.

Authors:  Marziyeh Tavassoli; Abolfazl Ardjmand
Journal:  Basic Clin Neurosci       Date:  2020-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.